|
Gene: CDC45 |
Gene summary for CDC45 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CDC45 | Gene ID | 8318 |
Gene name | cell division cycle 45 | |
Gene Alias | CDC45L | |
Cytomap | 22q11.21 | |
Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | O75419 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8318 | CDC45 | LZE7T | Human | Esophagus | ESCC | 1.02e-03 | 2.84e-01 | 0.0667 |
8318 | CDC45 | LZE21T | Human | Esophagus | ESCC | 8.02e-04 | 2.06e-01 | 0.0655 |
8318 | CDC45 | P1T-E | Human | Esophagus | ESCC | 2.97e-02 | 2.04e-01 | 0.0875 |
8318 | CDC45 | P2T-E | Human | Esophagus | ESCC | 7.98e-13 | 3.67e-01 | 0.1177 |
8318 | CDC45 | P4T-E | Human | Esophagus | ESCC | 2.81e-07 | 2.54e-01 | 0.1323 |
8318 | CDC45 | P5T-E | Human | Esophagus | ESCC | 4.24e-18 | 3.84e-01 | 0.1327 |
8318 | CDC45 | P10T-E | Human | Esophagus | ESCC | 2.05e-07 | 3.14e-01 | 0.116 |
8318 | CDC45 | P16T-E | Human | Esophagus | ESCC | 2.03e-09 | 2.56e-01 | 0.1153 |
8318 | CDC45 | P21T-E | Human | Esophagus | ESCC | 7.31e-14 | 4.72e-01 | 0.1617 |
8318 | CDC45 | P22T-E | Human | Esophagus | ESCC | 1.66e-02 | 1.24e-01 | 0.1236 |
8318 | CDC45 | P24T-E | Human | Esophagus | ESCC | 4.30e-10 | 2.85e-01 | 0.1287 |
8318 | CDC45 | P26T-E | Human | Esophagus | ESCC | 1.88e-04 | 2.16e-01 | 0.1276 |
8318 | CDC45 | P28T-E | Human | Esophagus | ESCC | 9.56e-08 | 1.79e-01 | 0.1149 |
8318 | CDC45 | P30T-E | Human | Esophagus | ESCC | 4.44e-04 | 4.38e-01 | 0.137 |
8318 | CDC45 | P31T-E | Human | Esophagus | ESCC | 3.89e-12 | 3.59e-01 | 0.1251 |
8318 | CDC45 | P32T-E | Human | Esophagus | ESCC | 1.30e-15 | 4.43e-01 | 0.1666 |
8318 | CDC45 | P37T-E | Human | Esophagus | ESCC | 3.40e-10 | 2.98e-01 | 0.1371 |
8318 | CDC45 | P48T-E | Human | Esophagus | ESCC | 3.75e-03 | 1.32e-01 | 0.0959 |
8318 | CDC45 | P52T-E | Human | Esophagus | ESCC | 1.13e-16 | 4.12e-01 | 0.1555 |
8318 | CDC45 | P65T-E | Human | Esophagus | ESCC | 3.99e-04 | 1.50e-01 | 0.0978 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00063023 | Oral cavity | OSCC | double-strand break repair | 132/7305 | 251/18723 | 7.93e-06 | 8.52e-05 | 132 |
GO:00315704 | Oral cavity | OSCC | DNA integrity checkpoint | 72/7305 | 123/18723 | 8.77e-06 | 9.31e-05 | 72 |
GO:00062611 | Oral cavity | OSCC | DNA-dependent DNA replication | 84/7305 | 151/18723 | 2.46e-05 | 2.30e-04 | 84 |
GO:0006270 | Oral cavity | OSCC | DNA replication initiation | 25/7305 | 34/18723 | 4.63e-05 | 3.90e-04 | 25 |
GO:0006310 | Oral cavity | OSCC | DNA recombination | 147/7305 | 305/18723 | 6.33e-04 | 3.56e-03 | 147 |
GO:0000725 | Oral cavity | OSCC | recombinational repair | 70/7305 | 140/18723 | 5.22e-03 | 2.03e-02 | 70 |
GO:0000724 | Oral cavity | OSCC | double-strand break repair via homologous recombination | 69/7305 | 138/18723 | 5.52e-03 | 2.14e-02 | 69 |
GO:0000727 | Oral cavity | OSCC | double-strand break repair via break-induced replication | 9/7305 | 12/18723 | 1.27e-02 | 4.24e-02 | 9 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDC45 | SNV | Missense_Mutation | novel | c.434N>A | p.Gly145Glu | p.G145E | O75419 | protein_coding | tolerated(0.25) | benign(0.04) | TCGA-A2-A0EP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
CDC45 | SNV | Missense_Mutation | c.1723G>A | p.Asp575Asn | p.D575N | O75419 | protein_coding | tolerated(0.06) | possibly_damaging(0.641) | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
CDC45 | SNV | Missense_Mutation | c.1777N>T | p.Leu593Phe | p.L593F | O75419 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A142-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamid | SD | |
CDC45 | SNV | Missense_Mutation | novel | c.1016N>A | p.Gly339Glu | p.G339E | O75419 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
CDC45 | insertion | Frame_Shift_Ins | novel | c.614_615insGCATTTGCTCCACCTTTTGTTCTCTTTGT | p.Asp205GlufsTer39 | p.D205Efs*39 | O75419 | protein_coding | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
CDC45 | insertion | In_Frame_Ins | novel | c.739_740insGGCATC | p.Asp247delinsGlyHisHis | p.D247delinsGHH | O75419 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
CDC45 | insertion | Nonsense_Mutation | novel | c.741_742insTGAGGAACACAGGGAG | p.Met248Ter | p.M248* | O75419 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
CDC45 | deletion | Frame_Shift_Del | novel | c.897delC | p.Cys299Ter | p.C299* | O75419 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
CDC45 | SNV | Missense_Mutation | novel | c.1132N>C | p.Glu378Gln | p.E378Q | O75419 | protein_coding | tolerated(0.07) | probably_damaging(0.913) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
CDC45 | SNV | Missense_Mutation | c.326N>C | p.Val109Ala | p.V109A | O75419 | protein_coding | deleterious(0.02) | benign(0.009) | TCGA-EK-A2PI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |